At NewLink Genetics, we are discovering, developing, and working to commercialize novel immuno-oncology therapies to fundamentally change the way cancer is treated. Through strategic alliances with others who share our vision, we have the opportunity to maximize our contributions to science and the patients who need us most.
In September 2017, we entered into a clinical collaboration agreement with AstraZeneca to evaluate the combination of indoximod, NewLink Genetics’ small molecule IDO pathway inhibitor, and durvalumab, AstraZeneca’s anti-PD-L1 monoclonal antibody, along with standard of care chemotherapy for patients with metastatic pancreatic cancer.
The Phase 2 trial will be funded equally by both companies, with NewLink Genetics serving as the study sponsor.
We are pleased to initiate this joint immuno-oncology clinical collaboration and have the opportunity to potentially address the significant unmet need for patients with pancreatic cancer.
In October 2014, we entered into an exclusive worldwide license and collaboration agreement with Genentech, which included a research collaboration for the discovery of next-generation IDO and TDO pathway inhibitors.* We may be eligible to receive milestone payments based on achievement of specific predetermined milestones as well as escalating royalties on potential commercial sales of multiple Genentech products. Genentech will fund future research, development, manufacturing and commercialization costs.
NewLink Genetics retains co-promotion rights for potential next-generation IDO and TDO compounds in the United States and will receive royalties on commercial sales.
It is our vision that through the strength of this leading oncology partnership, we will continue to expand our reach in order to improve the lives of patients with cancer.
We are also working with Merck & Co. to develop rVSV-ZEBOV,† a vaccine to target Ebola. As part of the agreement, NewLink Genetics received an up-front payment of $30 million from Merck. In February 2015, NewLink Genetics received a $20 million milestone payment after initiating a key clinical trial in Africa. NewLink Genetics and Merck also contracted with the Biomedical Advanced Research and Development Authority (BARDA) for an initial payment of $30 million, and in October 2015, received another $18 million to support further scale-up of manufacturing. In September 2015, NewLink Genetics also received $8.1 million, with future options up to $5.2 million, from the Defense Threat Reduction Agency (DTRA) to continue further research. The vaccine rVSV-ZEBOV was originally developed by the Public Health Agency of Canada (PHAC) and licensed by a wholly owned subsidiary of NewLink Genetics.
Partner with us
By partnering with other companies, we have many more opportunities to make a difference in the lives of patients with cancer. Our doors are open to new partnerships in immuno-oncology, where we’re investing in our collective future. For new partnership inquiries, please contact us.
*Licensed by Genentech. †Licensed by Merck & Co.